Scinai Immunotherapeutics Ltd
SCNI0.750USD
-0.012-1.57%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.14MMarket Cap
0.07P/E TTM
More Details of Scinai Immunotherapeutics Ltd Company
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Scinai Immunotherapeutics Ltd Info
Ticker SymbolSCNI
Company nameScinai Immunotherapeutics Ltd
IPO dateJun 07, 2007
CEOReichman (Amir)
Number of employees31
Security typeDepository Receipt
Fiscal year-endJun 07
AddressJerusalem Biopark, 2Nd Floor
CityJERUSALEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code00000
Phone97289302529
Websitehttps://www.scinai.com/
Ticker SymbolSCNI
IPO dateJun 07, 2007
CEOReichman (Amir)
Company Executives of Scinai Immunotherapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
+51.52%
Mr. Samuel J. Moed
Mr. Samuel J. Moed
Director
Director
--
--
Mr. Joshua Phillipson
Mr. Joshua Phillipson
Investor Relations
Investor Relations
--
--
Dr. Morris C. Laster, M.D.
Dr. Morris C. Laster, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 23
Updated: Sun, Nov 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RK Stone Miami, LLC
5.77%
LCK JNK 1 LLC
2.33%
Stone (Daniel E)
1.85%
Armistice Capital LLC
1.29%
Abalone Asset Management Ltd.
1.23%
Other
87.54%
Shareholders
Shareholders
Proportion
RK Stone Miami, LLC
5.77%
LCK JNK 1 LLC
2.33%
Stone (Daniel E)
1.85%
Armistice Capital LLC
1.29%
Abalone Asset Management Ltd.
1.23%
Other
87.54%
Shareholder Types
Shareholders
Proportion
Corporation
8.10%
Hedge Fund
2.54%
Individual Investor
2.20%
Investment Advisor
1.36%
Investment Advisor/Hedge Fund
0.84%
Other
84.96%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
20
247.18K
7.75%
+209.10K
2025Q2
33
391.87K
45.94%
+279.77K
2025Q1
34
424.61K
49.78%
+268.71K
2024Q4
29
225.02K
26.38%
+113.05K
2024Q3
33
172.68K
20.39%
+41.77K
2024Q2
34
145.50K
9.79%
-4.50K
2024Q1
37
164.38K
100.97%
+8.82K
2023Q4
39
169.63K
48.24%
+28.24K
2023Q3
42
134.35K
45.97%
+54.60K
2023Q2
41
94.79K
37.87%
-787.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
LCK JNK 1 LLC
80.76K
2.53%
+80.76K
--
Feb 09, 2025
Stone (Daniel E)
264.20K
8.29%
+201.80K
+323.40%
Sep 29, 2025
Armistice Capital LLC
44.80K
1.41%
+44.80K
--
Sep 30, 2024
Abalone Asset Management Ltd.
42.54K
1.33%
+24.54K
+136.35%
Jun 30, 2024
Sabby Management, LLC
29.05K
0.91%
+29.05K
--
Dec 31, 2024
Citadel Advisors LLC
11.60K
0.36%
+11.60K
--
Jun 30, 2025
Reichman (Amir)
8.08K
0.25%
+5.68K
+236.54%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
3.48K
0.11%
+1.92K
+122.27%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
SPDR Portfolio Developed World ex-US ETF
0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
Nov 23, 2022
Merger
10→1
Nov 23, 2022
Merger
10→1
Date
Type
Ratio
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
May 06, 2024
Merger
10→1
Nov 23, 2022
Merger
10→1
Nov 23, 2022
Merger
10→1
Nov 23, 2022
Merger
10→1
Nov 23, 2022
Merger
10→1
FAQs
Who are the top five shareholders of Scinai Immunotherapeutics Ltd?
The top five shareholders of Scinai Immunotherapeutics Ltd are:
LCK JNK 1 LLC holds 80.76K shares, accounting for 2.53% of the total shares.
Stone (Daniel E) holds 264.20K shares, accounting for 8.29% of the total shares.
Armistice Capital LLC holds 44.80K shares, accounting for 1.41% of the total shares.
Abalone Asset Management Ltd. holds 42.54K shares, accounting for 1.33% of the total shares.
Sabby Management, LLC holds 29.05K shares, accounting for 0.91% of the total shares.
LCK JNK 1 LLC holds 80.76K shares, accounting for 2.53% of the total shares.
Stone (Daniel E) holds 264.20K shares, accounting for 8.29% of the total shares.
Armistice Capital LLC holds 44.80K shares, accounting for 1.41% of the total shares.
Abalone Asset Management Ltd. holds 42.54K shares, accounting for 1.33% of the total shares.
Sabby Management, LLC holds 29.05K shares, accounting for 0.91% of the total shares.
What are the top three shareholder types of Scinai Immunotherapeutics Ltd?
The top three shareholder types of Scinai Immunotherapeutics Ltd are:
RK Stone Miami, LLC
LCK JNK 1 LLC
Stone (Daniel E)
RK Stone Miami, LLC
LCK JNK 1 LLC
Stone (Daniel E)
How many institutions hold shares of Scinai Immunotherapeutics Ltd (SCNI)?
As of 2025Q3, 20 institutions hold shares of Scinai Immunotherapeutics Ltd, with a combined market value of approximately 247.18K, accounting for 7.75% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -38.19%.
What is the biggest source of revenue for Scinai Immunotherapeutics Ltd?
In --, the -- business generated the highest revenue for Scinai Immunotherapeutics Ltd, amounting to -- and accounting for --% of total revenue.
